The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon - BioSpace

• The FDA has approved a novel regimen featuring iberdomide, a cereblon E3 ligase modulator (CELMoD), for the treatment of relapsed/refractory multiple myeloma (RRMM). • The treatment, used in combination with daratumumab and dexamethasone, is specifically effective for patients who have previously failed immunomodulatory drugs like lenalidomide and pomalidomide.

• Measles cases are reaching record highs as immunization rates drop across various parts of the United States. • Health officials warn that measles is one of the most contagious diseases in history and is typically the first to resurface when vaccine coverage declines.

• A new systematic review and meta-analysis of 720,000 adults has linked the consumption of artificial sweeteners to an increased risk of developing diabetes. • Separately, a study published in Frontiers in Nutrition indicates that cocoa polyphenols may enhance brain health by improving mood, blood flow, and the gut-brain axis.

• Recent research highlights the efficacy of GLP-1 medications, specifically semaglutide, in improving liver scarring for patients with advanced MASH and early cirrhosis. • A Mayo Clinic study identified a distinct biological subtype of obesity that responds more effectively to tirzepatide, a medication mimicking two appetite and blood sugar hormones.

• Doctors are distancing themselves from the World Health Organization (WHO) due to an ethics dispute regarding drug trial designs during an Ebola emergency. • The outbreak in eastern DRC since April has infected over 4,587 people and caused 2,130 deaths, including at least 151 healthcare workers by August 1.

• Eli Lilly and Company is urging online platforms, payment processors, and regulators to dismantle the illegal black market for retatrutide. • Retatrutide is currently an investigational molecule in Phase 3 clinical trials for obesity and type 2 diabetes and has not been approved for human use by any global regulatory agency.

• Outlook Therapeutics reported a $20.3 million loss for the third quarter, coinciding with the FDA approval of its intravitreal treatment, LYTENAVA. • Management projects that LYTENAVA could generate over $500 million in annual U.S. sales by 2030 due to its direct-to-retina delivery method.

• Helus Pharma has appointed Michael Halstead, the former President of Intra-Cellular Therapies, as its new Chief Executive Officer. • The company successfully completed patient enrollment for its Phase 3 APPROACH study evaluating the drug candidate HLP003.

• Thousands of people were sickened by Cyclospora after the parasite evaded U.S. food safety systems, highlighting critical gaps in contamination tracking. • The FDA cut a specific program for tracking Cyclospora outbreaks and delayed a rule that would have forced companies to provide supply chain records more quickly during investigations.

• Researchers are testing a novel approach to treating depression by using anti-inflammatory drugs to calm the immune system rather than targeting brain chemicals. • Early results from a small clinical trial indicate that this immune-focused strategy shows promise in alleviating depressive symptoms.

• The Medicines and Healthcare products Regulatory Agency (MHRA) is proposing a shake-up of the UK's medicines approval process to accelerate the development of treatments for rare diseases. • With approximately 10,000 rare diseases existing, the vast majority currently lack effective therapies, creating significant gaps in patient care.